Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005067 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT03005067 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 171 participants.
The verdict
NCT03005067, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.
Interventions
- OTHER Placebo
- DRUG Carbomer 980 (1146A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03005067
The ClinicalTrials.gov registry entry for NCT03005067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03005067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03005067 about?
NCT03005067 is a clinical study titled "To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold". This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.
What is the current status of trial NCT03005067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2016-12-29. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT03005067?
The interventions under investigation include: Placebo (OTHER), Carbomer 980 (1146A) (DRUG).
Who is sponsoring clinical trial NCT03005067?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.